These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27179602)

  • 21. Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype.
    Farrell GC; Mridha AR; Yeh MM; Arsov T; Van Rooyen DM; Brooling J; Nguyen T; Heydet D; Delghingaro-Augusto V; Nolan CJ; Shackel NA; McLennan SV; Teoh NC; Larter CZ
    Liver Int; 2014 Aug; 34(7):1084-93. PubMed ID: 24107103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
    Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
    Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.
    Afonso MB; Rodrigues PM; Carvalho T; Caridade M; Borralho P; Cortez-Pinto H; Castro RE; Rodrigues CM
    Clin Sci (Lond); 2015 Oct; 129(8):721-39. PubMed ID: 26201023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chokeberry attenuates the expression of genes related to de novo lipogenesis in the hepatocytes of mice with nonalcoholic fatty liver disease.
    Park H; Liu Y; Kim HS; Shin JH
    Nutr Res; 2016 Jan; 36(1):57-64. PubMed ID: 26773781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
    Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
    Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of nonalcoholic fatty liver disease model by high-fat diet in rats.
    Wardani HA; Rahmadi M; Ardianto C; Balan SS; Kamaruddin NS; Khotib J
    J Basic Clin Physiol Pharmacol; 2019 Nov; 30(6):. PubMed ID: 31760381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic biomarkers for non-alcoholic fatty liver disease induced by high-fat diet: In vivo magnetic resonance spectroscopy of hyperpolarized [1-
    Moon CM; Oh CH; Ahn KY; Yang JS; Kim JY; Shin SS; Lim HS; Heo SH; Seon HJ; Kim JW; Jeong GW
    Biochem Biophys Res Commun; 2017 Jan; 482(1):112-119. PubMed ID: 27562716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dietary intake of ain-93 standard diet induces Fatty liver with altered hepatic fatty acid profile in Wistar rats.
    Farias Santos J; Suruagy Amaral M; Lima Oliveira S; Porto Barbosa J; Rego Cabral C; Sofia Melo I; Bezerra Bueno N; Duarte Freitas J; Goulart Sant'ana A; Rocha Ataíde T
    Nutr Hosp; 2015 May; 31(5):2140-6. PubMed ID: 25929385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of tissue metal and trace element content in a rat model of non-alcoholic fatty liver disease using ICP-DRC-MS.
    Gatiatulina ER; Popova EV; Polyakova VS; Skalnaya AA; Agletdinov EF; Nikonorov AA; Skalny AV; Tinkov AA
    J Trace Elem Med Biol; 2017 Jan; 39():91-99. PubMed ID: 27908430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
    Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
    Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma fatty acid composition in French-Canadian children with non-alcoholic fatty liver disease: Effect of n-3 PUFA supplementation.
    Spahis S; Alvarez F; Dubois J; Ahmed N; Peretti N; Levy E
    Prostaglandins Leukot Essent Fatty Acids; 2015 Aug; 99():25-34. PubMed ID: 26066299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Translocator protein (18 kDa), a potential molecular imaging biomarker for non-invasively distinguishing non-alcoholic fatty liver disease.
    Xie L; Yui J; Hatori A; Yamasaki T; Kumata K; Wakizaka H; Yoshida Y; Fujinaga M; Kawamura K; Zhang MR
    J Hepatol; 2012 Nov; 57(5):1076-82. PubMed ID: 22796156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study.
    Parker HM; O'Connor HT; Keating SE; Cohn JS; Garg ML; Caterson ID; George J; Johnson NA
    Br J Nutr; 2015 Sep; 114(5):780-7. PubMed ID: 26202539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet.
    Ahn J; Lee H; Jung CH; Ha T
    Mol Nutr Food Res; 2012 Nov; 56(11):1665-74. PubMed ID: 22968990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endocrine Disruptor DDE Associated with a High-Fat Diet Enhances the Impairment of Liver Fatty Acid Composition in Rats.
    Rodríguez-Alcalá LM; Sá C; Pimentel LL; Pestana D; Teixeira D; Faria A; Calhau C; Gomes A
    J Agric Food Chem; 2015 Oct; 63(42):9341-8. PubMed ID: 26449595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research.
    Willebrords J; Pereira IV; Maes M; Crespo Yanguas S; Colle I; Van Den Bossche B; Da Silva TC; de Oliveira CP; Andraus W; Alves VA; Cogliati B; Vinken M
    Prog Lipid Res; 2015 Jul; 59():106-25. PubMed ID: 26073454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular interplay between Δ5/Δ6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis.
    López-Vicario C; González-Périz A; Rius B; Morán-Salvador E; García-Alonso V; Lozano JJ; Bataller R; Cofán M; Kang JX; Arroyo V; Clària J; Titos E
    Gut; 2014 Feb; 63(2):344-55. PubMed ID: 23492103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-alcoholic fatty liver disease (NAFLD) potentiates autoimmune hepatitis in the CYP2D6 mouse model.
    Müller P; Messmer M; Bayer M; Pfeilschifter JM; Hintermann E; Christen U
    J Autoimmun; 2016 May; 69():51-8. PubMed ID: 26924542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
    Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
    Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver-specific deletion of the signal transducer and activator of transcription 5 gene aggravates fatty liver in response to a high-fat diet in mice.
    Baik M; Nam YS; Piao MY; Kang HJ; Park SJ; Lee JH
    J Nutr Biochem; 2016 Mar; 29():56-63. PubMed ID: 26895665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.